DiscoverResearch To Practice | Oncology VideosOcular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2  — An Interview with Dr Neel Pasricha on Adverse Event Management

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Update: 2025-09-16
Share

Description

Featuring an interview with Dr Neel Pasricha, including the following topics:

  • Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00 )
  • Association of corneal toxicities with ADCs (4:56 )
  • Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02 )
  • Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44 )
  • Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55 )
  • Other ocular toxicities associated with cancer therapies (24:26 )
  • Prevention and management of corneal toxicity (33:58 )
  • Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39 )
  • General clinical pearls on the management of ocular toxicities with cancer therapies (48:04 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2  — An Interview with Dr Neel Pasricha on Adverse Event Management

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Dr. Neil Love